Renal Cell Cancer Treated with a Single-Edged Sword

Preclinical and early clinical data suggest that antiangiogenic treatments may lead to more aggressive tumors. In this issue of Cell Reports, Blagoev et al. (2013) show that sunitinib, a multikinase inhibitor with antiangiogenic effects, does not worsen the survival of patients with metastatic kidne...

Full description

Saved in:
Bibliographic Details
Published in:Cell reports (Cambridge) 2013-02, Vol.3 (2), p.275-276
Main Authors: Lim, Emerson, Gelmann, Edward P.
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Carcinoma, Renal Cell - drug therapy
Humans
Indoles - therapeutic use
Kidney Neoplasms - drug therapy
Pyrroles - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Preclinical and early clinical data suggest that antiangiogenic treatments may lead to more aggressive tumors. In this issue of Cell Reports, Blagoev et al. (2013) show that sunitinib, a multikinase inhibitor with antiangiogenic effects, does not worsen the survival of patients with metastatic kidney cancer.
ISSN:2211-1247
2211-1247
DOI:10.1016/j.celrep.2013.02.001